{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T08:31:21Z","timestamp":1783240281562,"version":"3.54.6"},"reference-count":52,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.nmd.2020.06.005","type":"journal-article","created":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T11:42:13Z","timestamp":1591962133000},"page":"599-610","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Oral bisphosphonate treatment in patients with Duchenne muscular dystrophy on long term glucocorticoid therapy"],"prefix":"10.1016","volume":"30","author":[{"given":"Cuixia","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda L.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey","family":"Hornung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane C.","family":"Khoury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Rybalsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen C.","family":"Shellenbarger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meilan M.","family":"Rutter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.nmd.2020.06.005_bib0001","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/ana.23528","article-title":"Evidence-based path to newborn screening for Duchenne muscular dystrophy","volume":"71","author":"Mendell","year":"2012","journal-title":"Ann Neurol"},{"issue":"6","key":"10.1016\/j.nmd.2020.06.005_bib0002","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1007\/s00246-005-0909-4","article-title":"Steroid therapy and cardiac function in Duchenne muscular dystrophy","volume":"26","author":"Markham","year":"2005","journal-title":"Pediatr Cardiol"},{"issue":"4","key":"10.1016\/j.nmd.2020.06.005_bib0003","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.nmd.2006.01.010","article-title":"Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade","volume":"16","author":"Biggar","year":"2006","journal-title":"Neuromuscul Disord"},{"issue":"4","key":"10.1016\/j.nmd.2020.06.005_bib0004","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1177\/000992280304200408","article-title":"Vertebral fractures in boys with Duchenne muscular dystrophy","volume":"42","author":"Bothwell","year":"2003","journal-title":"Clin Pediatr"},{"issue":"1","key":"10.1016\/j.nmd.2020.06.005_bib0005","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/01241398-200001000-00016","article-title":"Bone mineral density and fractures in boys with Duchenne muscular dystrophy","volume":"20","author":"Larson","year":"2000","journal-title":"J Pediatr Orthop"},{"issue":"11\u201312","key":"10.1016\/j.nmd.2020.06.005_bib0006","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.nmd.2007.05.008","article-title":"Low bone mineral density and decreased bone turnover in Duchenne muscular dystrophy","volume":"17","author":"Soderpalm","year":"2007","journal-title":"Neuromuscul Disord"},{"issue":"9","key":"10.1016\/j.nmd.2020.06.005_bib0007","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1359\/jbmr.060601","article-title":"Association between bone mass and fractures in children: a prospective cohort study","volume":"21","author":"Clark","year":"2006","journal-title":"J Bone Miner Res"},{"issue":"3","key":"10.1016\/j.nmd.2020.06.005_bib0008","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1359\/jbmr.091007","article-title":"The relationship between fractures and DXA measures of BMD in the distal femur of children and adolescents with cerebral palsy or muscular dystrophy","volume":"25","author":"Henderson","year":"2010","journal-title":"J Bone Miner Res"},{"issue":"1","key":"10.1016\/j.nmd.2020.06.005_bib0009","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1359\/jbmr.1998.13.1.143","article-title":"Bone mineral density in girls with forearm fractures","volume":"13","author":"Goulding","year":"1998","journal-title":"J Bone Miner Res"},{"issue":"3","key":"10.1016\/j.nmd.2020.06.005_bib0010","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0960-8966(01)00307-8","article-title":"Vertebral compression in Duchenne muscular dystrophy following deflazacort","volume":"12","author":"Talim","year":"2002","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2020.06.005_bib0011","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.jpeds.2016.11.078","article-title":"Long-term outcome of interdisciplinary management of patients with dechenne muscular dystrophy receiving daily glucocorticoid treatment","volume":"182","author":"Wong","year":"2017","journal-title":"J Pediatr"},{"issue":"Suppl 1","key":"10.1016\/j.nmd.2020.06.005_bib0012","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/S0960-8966(10)70026-2","article-title":"UK North Star Neuromuscular Clinical Network (NSCN): National audit results in Duchenne muscular dystrophy (DMD) corticosteroid practice, vitamin D status and bone health","volume":"20","author":"Manzur","year":"2010","journal-title":"Neuromuscul Disord"},{"issue":"12","key":"10.1016\/j.nmd.2020.06.005_bib0013","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.nmd.2012.06.354","article-title":"Bone health in boys with Duchenne Muscular Dystrophy on long-term daily deflazacort therapy","volume":"22","author":"Mayo","year":"2012","journal-title":"Neuromuscul Disord"},{"issue":"10","key":"10.1016\/j.nmd.2020.06.005_bib0014","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1469-8749.2002.tb00272.x","article-title":"Fracture prevalence in Duchenne muscular dystrophy","volume":"44","author":"McDonald","year":"2002","journal-title":"Dev Med Child Neurol"},{"issue":"6","key":"10.1016\/j.nmd.2020.06.005_bib0015","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/0736-4679(92)90529-3","article-title":"Fat embolism syndrome in a child with muscular dystrophy","volume":"10","author":"Pender","year":"1992","journal-title":"J Emerg Med"},{"key":"10.1016\/j.nmd.2020.06.005_bib0016","first-page":"1","article-title":"Interventions to prevent and treat corticosteroid-induced osteoporosis and prevent osteoporotic fractures in Duchenne muscular dystrophy","author":"Bell","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.nmd.2020.06.005_bib0017","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.nmd.2004.09.010","article-title":"Bone health in Duchenne muscular dystrophy: a workshop report from the meeting in Cincinnati, Ohio, July 8, 2004","volume":"15","author":"Biggar","year":"2005","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"10.1016\/j.nmd.2020.06.005_bib0018","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.nmd.2004.09.009","article-title":"Report of a Muscular Dystrophy Campaign funded workshop Birmingham, UK, January 16th 2004. Osteoporosis in Duchenne muscular dystrophy; its prevalence, treatment and prevention","volume":"15","author":"Quinlivan","year":"2005","journal-title":"Neuromuscul Disord"},{"issue":"11","key":"10.1016\/j.nmd.2020.06.005_bib0019","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.nmd.2010.07.272","article-title":"170th ENMC International Workshop: bone protection for corticosteroid treated Duchenne muscular dystrophy. 27\u201329 November 2009, Naarden, the Netherlands","volume":"20","author":"Quinlivan","year":"2010","journal-title":"Neuromuscul Disord"},{"issue":"3","key":"10.1016\/j.nmd.2020.06.005_bib0020","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.nmd.2010.02.007","article-title":"Best practice in Duchenne muscular dystrophy","volume":"20","author":"Quinlivan","year":"2010","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2020.06.005_bib0021","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1474-4422(18)30025-5","article-title":"Diagnosis and Management of DMD, part 2","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet"},{"issue":"suppl 2","key":"10.1016\/j.nmd.2020.06.005_bib0022","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1542\/peds.2018-0333E","article-title":"Bone health and osteoporosis management of the patient with DMD","volume":"142","author":"Ward","year":"2018","journal-title":"Pediatrics"},{"issue":"4","key":"10.1016\/j.nmd.2020.06.005_bib0023","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1517\/21678707.2016.1148596","article-title":"Bisphosphonate use in Duchenne Muscular Dystrophy \u2013 why, when to start and when to stop","volume":"4","author":"Wood","year":"2016","journal-title":"Exp Opin Orphan Drugs"},{"issue":"4","key":"10.1016\/j.nmd.2020.06.005_bib0024","first-page":"245","article-title":"Clinical use of bisphosphonates in children","volume":"3","author":"Somalo","year":"2007","journal-title":"World J Pediatr"},{"issue":"11","key":"10.1016\/j.nmd.2020.06.005_bib0025","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.nmd.2016.08.011","article-title":"Bone health measures in glucocorticoid-treated ambulatory boys with Duchenne muscular dystrophy","volume":"26","author":"Tian","year":"2016","journal-title":"Neuromuscul Disord"},{"issue":"10","key":"10.1016\/j.nmd.2020.06.005_bib0026","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1210\/jc.2011-1111","article-title":"Revised reference curves for bone mineral content and areal bone mineral density according to age and sex for black and non-black children: results of the bone mineral density in childhood study","volume":"96","author":"Zemel","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.nmd.2020.06.005_bib0027","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/ppul.10239","article-title":"Correlation between standing height, sitting height, and arm span as an index of pulmonary function in 6\u201310-year-old children","volume":"36","author":"Torres","year":"2003","journal-title":"Pediatr Pulmonol"},{"issue":"7","key":"10.1016\/j.nmd.2020.06.005_bib0028","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1469-8749.2004.tb00508.x","article-title":"Height prediction from ulna length","volume":"46","author":"Gauld","year":"2004","journal-title":"Dev Med Child Neurol"},{"issue":"2","key":"10.1016\/j.nmd.2020.06.005_bib0029","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2214\/ajr.178.2.1780439","article-title":"Pediatric reference data for dual X-ray absorptiometric measures of normal bone density in the distal femur","volume":"178","author":"Henderson","year":"2002","journal-title":"Am J Roentgenol"},{"key":"10.1016\/j.nmd.2020.06.005_bib0030","unstructured":"2019 ISCD official positions - Pediatric: https:\/\/www.iscd.org\/official-positions\/2019-iscd-official-positions-pediatric\/ 2019 [accessed 22 January 2020]."},{"issue":"246","key":"10.1016\/j.nmd.2020.06.005_bib0031","first-page":"1","article-title":"2000 CDC growth charts for the United States: methods and development","volume":"11","author":"Kuczmarski","year":"2002","journal-title":"Vital Health Stat"},{"issue":"2","key":"10.1016\/j.nmd.2020.06.005_bib0032","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.apmr.2004.04.021","article-title":"Alendronate in the treatment of low bone mass in steroid-treated boys with Duchenne's muscular dystrophy","volume":"86","author":"Hawker","year":"2005","journal-title":"Arch Phys Med Rehabil"},{"issue":"4","key":"10.1016\/j.nmd.2020.06.005_bib0033","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/mus.23948","article-title":"Bone density and alendronate effects in Duchenne muscular dystrophy patients","volume":"49","author":"Houston","year":"2014","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1016\/j.nmd.2020.06.005_bib0034","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/mus.24991","article-title":"Prophylactic oral bisphosphonate therapy in Duchenne muscular dystrophy","volume":"54","author":"Srinivasan","year":"2016","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2020.06.005_bib0035","first-page":"196","article-title":"Risedronate use in Duchenne Muscular Dystrophy: a pilot randomised control trial","volume":"82","author":"McSweeney","year":"2014","journal-title":"Horm Res Pediatr"},{"issue":"11","key":"10.1016\/j.nmd.2020.06.005_bib0036","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1007\/s00198-012-1911-3","article-title":"The use of intravenous bisphosphonate therapy to treat vertebral fractures due to osteoporosis among boys with Duchenne muscular dystrophy","volume":"23","author":"Sbrocchi","year":"2012","journal-title":"Osteoporos Int"},{"issue":"2","key":"10.1016\/j.nmd.2020.06.005_bib0037","doi-asserted-by":"crossref","first-page":"e353","DOI":"10.1542\/peds.2010-1666","article-title":"Impact of bisphosphonates on survival for patients with Duchenne muscular dystrophy","volume":"127","author":"Gordon","year":"2011","journal-title":"Pediatrics"},{"issue":"9","key":"10.1016\/j.nmd.2020.06.005_bib0038","first-page":"1478","article-title":"Different patterns of global and regional skeletal uptake of 99mTc-methylene diphosphonate with age: relevance to the pathogenesis of bone loss","volume":"41","author":"Carnevale","year":"2000","journal-title":"J Nucl Med"},{"issue":"10","key":"10.1016\/j.nmd.2020.06.005_bib0039","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1124\/dmd.108.021071","article-title":"Biodistribution and plasma protein binding of zoledronic acid","volume":"36","author":"Weiss","year":"2008","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"10.1016\/j.nmd.2020.06.005_bib0040","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.bone.2006.04.004","article-title":"Vertebral morphometry in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate treatment","volume":"39","author":"Land","year":"2006","journal-title":"Bone"},{"issue":"12","key":"10.1016\/j.nmd.2020.06.005_bib0041","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1002\/jbmr.2567","article-title":"Intravenous bisphosphonate therapy of young children with osteogenesis imperfecta: skeletal findings during follow up throughout the growing years","volume":"30","author":"Palomo","year":"2015","journal-title":"J Bone Miner Res"},{"issue":"2","key":"10.1016\/j.nmd.2020.06.005_bib0042","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1210\/jc.2010-0636","article-title":"Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study","volume":"96","author":"Ward","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.nmd.2020.06.005_bib0043","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1359\/JBMR.051006","article-title":"Two-Year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta","volume":"21","author":"DiMeglio","year":"2006","journal-title":"J Bone Miner Res"},{"issue":"5","key":"10.1016\/j.nmd.2020.06.005_bib0044","first-page":"1148","article-title":"A metaanalysis on the use of bisphosphonates in corticosteroid induced osteoporosis","volume":"26","author":"Homik","year":"1999","journal-title":"J Rheumatol"},{"key":"10.1016\/j.nmd.2020.06.005_bib0045","article-title":"Bisphosphonates for steroid-induced osteoporosis","volume":"10","author":"Allen","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.nmd.2020.06.005_bib0046","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1001\/jamaneurol.2019.0242","article-title":"Fractures and linear growth in a nationwide cohort of boys with Duchenne muscular dystrophy with and without glucocorticoid treatment: results from the UK NorthStar Database","volume":"76","author":"Joseph","year":"2019","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.nmd.2020.06.005_bib0047","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","article-title":"Vertebral fracture assessment using a semiquantitative technique","volume":"8","author":"Genant","year":"1993","journal-title":"J Bone Miner Res"},{"issue":"7","key":"10.1016\/j.nmd.2020.06.005_bib0048","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.nmd.2019.05.002","article-title":"Rhabdomyolysis and myoglobinuria following bisphosphonate infusion in patients with Duchenne muscular dystrophy","volume":"29","author":"Lemon","year":"2019","journal-title":"Neuromuscul Disord"},{"issue":"10","key":"10.1016\/j.nmd.2020.06.005_bib0049","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.nmd.2018.08.004","article-title":"Myoglobinuria in two patients with Duchenne muscular dystrophy after treatment with zoledronate: a case-report and call for caution","volume":"28","author":"Ivanyuk","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2020.06.005_bib0050","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.bone.2019.01.003","article-title":"Outcomes following intravenous bisphosphonate infusion in pediatric patients: a 7-year retrospective chart review","volume":"121","author":"Nasomyont","year":"2019","journal-title":"Bone"},{"issue":"12","key":"10.1016\/j.nmd.2020.06.005_bib0051","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.1007\/s00198-016-3761-x","article-title":"Effects of teriparatide on bone mineral density and quality of life in Duchenne muscular dystrophy related osteoporosis: a case report","volume":"27","author":"Catalano","year":"2016","journal-title":"Osteoporos Int"},{"issue":"2","key":"10.1016\/j.nmd.2020.06.005_bib0052","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.2106\/JBJS.CC.17.00190","article-title":"Efficacy of denosumab for glucocorticoid-induced osteoporosis in an adolescent patient with Duchenne muscular dystrophy a case report","volume":"8","author":"Kumaki","year":"2018","journal-title":"J Bone Jt Surg"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896620301553?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896620301553?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:10:06Z","timestamp":1760775006000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896620301553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":52,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S0960896620301553"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2020.06.005","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral bisphosphonate treatment in patients with Duchenne muscular dystrophy on long term glucocorticoid therapy","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2020.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}